Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
News|Articles|July 11, 2025
The Future of Drug Pricing: Most Favored Nation, PBMs, and Patient Access
Author(s)Laura Joszt, MA
During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.
Advertisement
Advertisement
During a conversation on the Trump administration’s 2025 drug pricing policies, panelists discussed the implications of the Most Favored Nation (MFN) order, the broader context of drug pricing reforms, and efforts to address pharmacy benefit manager (PBM) reform through greater transparency. Watch the
Related to this article
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
Advertisement
Advertisement